Search
Encorafenib
go.drugbank.com/drugs/DB11718ApprovedInvestigationalEncorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. … [L12216] This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion.
Encenicline
go.drugbank.com/drugs/DB11726InvestigationalEncenicline has been investigated for the treatment of Cognition, Schizophrenia, Alzheimer's Disease, Cardiac Repolarization, and Central Nervous System Diseases.
Icotinib
go.drugbank.com/drugs/DB11737Investigational. was given a “May Proceed” from the US FDA to conduct a Phase I study for the evaluation of icotinib as a treatment of EGFR+ Non-Small Cell Lung Cancer (NSCLC). … Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc
Vonoprazan
go.drugbank.com/drugs/DB11739ApprovedInvestigationalVonoprazan is a potassium-competitive acid blocker (PCAB) that inhibits H<sup>+</sup>, K<sup>+</sup>-ATPase-mediated gastric acid secretion. … [A253702] In May 2022, the FDA approved the use of vonoprazan in a co-packaged product containing amoxicillin and clarithromycin for the treatment of _H. pylori_ infection.
Ebastine
go.drugbank.com/drugs/DB11742ApprovedInvestigationalWithdrawnEbastine is under investigation for the treatment of Irritable Bowel Syndrome (IBS). Ebastine has been investigated for the treatment of Urticaria.
Benfotiamine
go.drugbank.com/drugs/DB11748ApprovedInvestigationalWithdrawnBenfotiamine has been investigated for the treatment and prevention of Diabetic Nephropathy and Diabetes Mellitus, Type 2.
Categories: Compounds used in a research, industrial, or household settingArpraziquantel
go.drugbank.com/drugs/DB11749Investigational(R)-Praziquantel is under investigation in clinical trial NCT02271984 (Relative Bioavailability Trial of L-Praziquantel in Healthy Volunteers).
Synonyms: L-PZQ, L-praziquantelCabotegravir
go.drugbank.com/drugs/DB11751ApprovedInvestigationalCabotegravir, or GSK1265744, is an HIV-1 integrase inhibitor that is prescribed with the non-nucleoside reverse transcriptase inhibitor, rilpivirine. Early research into cabotegravir showed it had lower oral bioavailability than dolutegr...
Talazoparib
go.drugbank.com/drugs/DB11760ApprovedInvestigationalTalazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair. Developed by Pfizer, talazoparib wa...
Categories: P-glycoprotein substrates with a Narrow Therapeutic IndexTenapanor
go.drugbank.com/drugs/DB11761ApprovedInvestigationalTenapanor is a novel, small molecule medication approved in September 2019 for the treatment of constipation-predominant irritable bowel-syndrome (IBS-C). … A185492] As an inhibitor of the sodium/hydrogen exchanger isoform 3 (NHE3) transporter, it is the first and currently only medication within its class[A185489,A185492,A185495] and therefore exists as a